RT Journal Article
T1 Protective Effect of Placental Mesenchymal Stromal Cells in an In Vitro Model of Parkinson's Disease Using Differentiated Neuroblastoma Cells
A1 Almudena Coto-Vilcapoma, 
A1 Laura Sánchez-Carretero, 
A1 Daniel Arenas-Gonzalez, 
A1 José A Molina, 
A1 María José Morán-Jiménez, 
A1 Paz de la Torre, 
A1 Ana I Flores, 
A1 Merino Martín, José Joaquín
AB Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder. It is characterized by the accumulation of misfolded α-synuclein (α-syn) and progressive loss of dopaminergic neurons in the substantia nigra. Due to the limitations of current therapies, mesenchymal stromal cell (MSC) transplantation has emerged as a promising neuroprotective strategy. This study evaluated the neuroprotective potential of decidua-derived mesenchymal stromal cells (DMSCs) in vitro using a human neuroblastoma cell line (NB69) exposed to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) as a PD model. The NB69 cells were differentiated into a mature dopaminergic phenotype using dibutyryl cyclic adenosine monophosphate (dbcAMP) and then exposed to MPP+. In proliferative NB69 cells, the effect of DMSCs was masked by their inherent antitumor activity against the neuroblastoma phenotype. Conversely, in the differentiated NB69 model, DMSCs demonstrated a significant protective role against MPP+-induced cytotoxicity. Interestingly, the mechanism by which DMSCs might exert a neuroprotective effect against MPP+ damage in differentiated NB69 cells appears to involve improving mitochondrial function by reducing free radicals. In summary, these findings suggest that DMSCs exert a neuroprotective effect in a dopaminergic-like context and highlight the importance of using differentiated cell models to accurately evaluate cell-based therapies for PD in the striatum.
PB MDPI
YR 2026
FD 2026
LK https://hdl.handle.net/20.500.14352/136752
UL https://hdl.handle.net/20.500.14352/136752
LA eng
NO Coto-Vilcapoma A, Sánchez-Carretero L, Arenas-Gonzalez D, et al. Protective Effect of Placental Mesenchymal Stromal Cells in an In Vitro Model of Parkinson’s Disease Using Differentiated Neuroblastoma Cells. IJMS 2026;27:3925. https://doi.org/10.3390/ijms27093925
NO ASOCIACIÓN PARKINSON MADRID (España)   This research was also funded by Grant PID2022-140785OB-I00 funded by MCIN/AEI/10.13039/501100011033/ FEDER, UE. Moreover, the project has received two grants for the hiring of Laboratory Technicians from the Comunidad de Madrid in 2016 and 2020 (Youth Employment Operational Program (YEI): Contracts for Research assistants and laboratory technicians of the Community of Madrid and the European Social Fund, PEJ16/MED/TL-1388 and PEJ-2020-TL/BMD-19230), and a grant for the contract of a research assistant (PEJ-2024-AI/SAL-GL-33566).
NO FUNDACIÓN NEUROCIENCIAS Y ENVEJECIMIENTO (España)
NO FUNDACIÓN FRANCISCO SORIA MELGUIZO (España)
NO INSTITUTO DE SALUD CARLOS III (España)
NO European Commission
NO Ministerio de Ciencia e Innovación (España)
DS Docta Complutense
RD 11 jun 2026